Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
By Mitchell Dowsett, I. Šestak, E. López-Knowles, K. Sidhu, A. Dunbier, J. Cowens, S. Ferree, J. Storhoff, C. Schaper, Jack Cuzick. Journal of Clinical Oncology, 2013
624 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/3f54df78c9264d4bf2cd3a4e1ad7d905c27c58c9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
In Oncology
Citations in the corpus
- Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, background): “reported a 50-gene classifier (PAM50, which contains mostly hormone receptor and proliferation related genes, and genes exhibiting myoepithelial and basal features), which has significant prognostic and predictive values on breast tumors [18-20] and can be widely applied in the clinical setting [21]”
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, methodology): “The PAM50-ROR test assists with the decision about adjuvant therapy in patients with ER/PgR-positive, HER2-negative (node-negative) breast cancer.(34-36) Chemotherapy should be considered for patients in the PAM50 high-risk group, but is not indicated for patients in the low-risk group.”
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, neutral): “Several of the multiparameter molecular markers have been used for this purpose [17, 18].”
- Clinical implications of the intrinsic molecular subtypes of breast cancer. (2015, neutral): “This has now been observed in multiple retrospective datasets, including 6 phase III clinical trials (i.e. CALGB9741 [45], GEICAM9906 [46], TransATAC [19], ABCSG-08 [20], MA.5 [47] and MA.12 [17] trials) coming from different countries and populations and with different adjuvant systemic therapies (”